Alzheimer’s disease drug development pipeline: 2024

Cited by (334)

Items 101–200 of 334

1. Anti-amyloid treatments in Alzheimer’s disease: elegance, evidence and ethics
   Timothy P Daly, Andi Olluri, Markku Tapio Kurkinen · 2024 · Advances in Clinical and Experimental Medicine
2. Discovery of structurally intriguing diterpenoids as anti-neuroinflammatory agents from mangrove plant Excoecaria agallocha L. via inhibiting macrophage polarization and inflammasome
   Junyi Li, Mingbin Chen, Tingting Fu, Fei‐Fei Liu, Jin Liu, Congjun Xu, Jing Zhou, Yong Rao, Zhongping Jiang, Ling Huang · 2025 · Phytochemistry
3. Long‐term value of lecanemab to individuals and families
   Bryan Tysinger, Yifan Wei, Hanke Heun‐Johnson, Julie Zissimopoulos · 2025 · Alzheimer s & Dementia Translational Research & Clinical Interventions
4. Basic approach on the protective effects of hesperidin and naringin in Alzheimer’s disease
   Müjgan Kuşi, Eda Becer, Seda Vatansever · 2024 · Nutritional Neuroscience
5. Commonly prescribed multi‐medication therapies exert sex‐specific effects on Alzheimer's disease pathology and metabolomic profiles in App NL‐G‐F mice: Implications for personalized therapeutics in aging
   Francesca Eroli, Kristina Johnell, Zeynep Acararicin, Christina Tsagkogianni, Stefania Zerial, Saverio Lancia, María Latorre‐Leal, Vilma Alanko, Sarah Nicole Hilmer, Anna Matton et al. · 2025 · Alzheimer s & Dementia
6. Identifying RAGE inhibitors as potential therapeutics for Alzheimer’s disease via integrated in-silico approaches
   Inderjeet Bhogal, Vaishali Pankaj, Sudeep Roy · 2025 · Scientific Reports
7. From suspicion of cognitive decline to dementia diagnosis: a systematic review of healthcare professionals’ considerations and attitudes
   Fleur C W Visser, Marleen Kloppenburg-Lagendijk, Liesbeth Hempenius, Nicolaas A. Verwey, Marieke Perry, Marlise E. A. van Eersel, Barbara C. Van Munster · 2025 · Age and Ageing
8. Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers
   Jeffrey Murray Burns, Susan Alford, Justine Coppinger, Martí Jiménez‐Mausbach, Sutapa Ray, Hemant Pandey, Rosemary D. Laird · 2026 · Alzheimer s & Dementia
9. Potential therapeutic targets for trauma management
   Zizheng Li, Ou Qiao, Yuru Wang, Ning Li, Yanhua Gong · 2023 · Trends in Pharmacological Sciences
10. Etiology of Late-Onset Alzheimer’s Disease, Biomarker Efficacy, and the Role of Machine Learning in Stage Diagnosis
    Manash Sarma, Subarna Chatterjee · 2024 · Diagnostics
11. Advances of therapeutic strategies for Alzheimer’s disease
    Xing Guo, Rui-zhu Yue, Zhen Cui, Shuying Wang, Tian Jia, Wenqiang Li, Wei Zhang, Linlin Shan, Chaokun Li · 2025 · Journal of Neurology
12. Developing theragnostics for Alzheimer's disease: Insights from cancer treatment
    Hyunju Lee, Hee-Jeong Choi, Yoo Joo Jeong, Y. Na, Jin Tae Hong, Ji Min Han, Hyang‐Sook Hoe, Key‐Hwan Lim · 2024 · International Journal of Biological Macromolecules
13. Zooming in on brain inflammation in Alzheimer’s disease
    Wiesje M. van der Flier, Michael Thomas Heneka · 2025 · Brain
14. Oxidative Stress and the Role of Immune Cells in Alzheimer’s Disease: Therapeutic Implications and Future Perspectives
    Nidhi Puranik, Minseok Song · 2025 · CNS & Neurological Disorders - Drug Targets
15. Biological Effects of Dietary Restriction on Alzheimer's Disease: Experimental and Clinical Investigations
    Zijiao Liu, Jun Zhang, Fei Jiang, Cong Liu, Yaping Shao, Weidong Le · 2025 · CNS Neuroscience & Therapeutics
16. CD2AP at the junction of nephropathy and Alzheimer’s disease
    Milène Vandal, Mohsen Janmaleki, Isabel M. Rea, Colin Gunn, Sotaro Hirai, Jeff A. Biernaskie, Justin Chun, Grant Robert Gordon, Andréy S. Shaw, Amir Sanati‐Nezhad et al. · 2025 · Molecular Neurodegeneration
17. Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer’s Disease: A U.S. Cost Comparison Model
    Amir Abbas Tahami Monfared, S. Barrows, Lindsey Fox, Brittney Herbel, William L. Herring, Alisha Krumbach, Quanwu Zhang · 2025 · Neurology and Therapy
18. A novel biochemical analysis for ApoE4 quantification in plasma and discrimination of homozygous and heterozygous APOE ε4 carriers
    Rodríguez, Andrés, Calero, Olga, Veiga, Sergio, Menacho-Román, Miriam, Arribas, Ignacio, Cano, Lluís, García-Ribas, Guillermo, Calero, Miguel · 2025 · Alzheimer's Research & Therapy
19. Structure–activity relationship of GSK-3β inhibitors: insight into drug design for Alzheimer's disease
    G. Rajamani, S.N.H. Naqvi, Abha Sharma · 2025 · RSC Medicinal Chemistry
20. P2Y1 receptor in Alzheimer’s disease
    Shan Luo, Yifei Wang, Tatsuhiro Hisatsune · 2024 · Neural Regeneration Research
21. Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review
    Hanane Doumar, Hicham El Mostafi, Aboubaker Elhessni, Mohamed Ebn Touhami, Abdelhalem Mesfioui · 2024 · IBRO Neuroscience Reports
22. Electrophysiological insights into Alzheimer's disease: A review of human and animal studies
    Kirsten Calvin, Adam M. McNeela, Amanda M. Leisgang Osse, Guncha Bhasin, Matthew Ridenour, Jefferson W. Kinney, J.M. Hyman · 2024 · Neuroscience & Biobehavioral Reviews
23. Harnessing artificial intelligence to transform Alzheimer’s disease research
    Sandrine Andrieu, Randall John Bateman, Erika Bereczki, Niranjan Bose, Anthony J. Brookes, Pudugramam Murali Doraiswamy, Miia Kivipelto, Susan L. Kohlhaas, Lampros C. Kourtis, Lefkos T. Middleton et al. · 2025 · Nature Medicine
24. Clinically meaningful benefit and real‐world evidence in Alzheimer's disease research and care
    Robert Perneczky, Lutz Froelich · 2025 · Alzheimer s & Dementia Translational Research & Clinical Interventions
25. microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients
    Penning, Amber, Snoeck, Sarah, Ormaechea, Olmo Ruiz, Ayyildiz, Dilara, Polzer, Oliver, Buitrago-Arango, Martin, Capobianco, Raffaella, de Winter, Fred, Balusu, Sriram, Verhaagen, Joost et al. · 2026 · Acta Neuropathologica Communications
26. Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
    Linda J. Van Eldik, Eric Siemers, Emily C. Collins, Michael Gold, David B. Henley, Peter Johannsen, Hans Jörg Möbius, Melanie B. Shulman, Jin Zhou, Marı́a C. Carrillo et al. · 2024 · Alzheimer s & Dementia Translational Research & Clinical Interventions
27. Inhibition of BET proteins modulates amyloid-beta accumulation and cognitive performance in middle-aged mice prenatally exposed to maternal immune activation
    Marta Matuszewska, Anna Wilkaniec, Magdalena Gąssowska-Dobrowolska, Magdalena Cieślik, Gabriela Olech-Kochańczyk, Ewelina Pałasz, Elżbieta Gawinek, Marcin Strawski, Grzegorz Arkadiusz Czapski · 2025 · Frontiers in Molecular Neuroscience
28. Alzheimer’s disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography
    Juliette H. Lanskey, Amirhossein Jafarian, Laura E. Hughes, Melek Karadag, Ece Kocagöncü, Matthew A Rouse, Natalie Adams, Michelle Naessens, Vanessa Raymont, Mark W. Woolrich et al. · 2025 · Molecular Psychiatry
29. Calcium and Non-Penetrating Traumatic Brain Injury: A Proposal for the Implementation of an Early Therapeutic Treatment for Initial Head Insults
    Danton H. O’Day · 2024 · Biomolecules
30. Olfactory Ecto-Mesenchymal Stem Cells in Modeling and Treating Alzheimer’s Disease
    Hongmin Wang, Abena Dwamena · 2024 · International Journal of Molecular Sciences
31. Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
    A. Panwar, Mohd Imran Khan, Rajesh Kumar, Rakesh Kumar, Santosh Kumar Rai, Anil Kumar · 2024 · Advances in Alzheimer's Disease
32. Towards a new Value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study
    Camillo Marra, Flavia Beccia, Paolo Caffarra, Federica L’Abbate, Federica Agosta, Alberto Benussi, Laura Bonanni, Amalia Cecilia Bruni, Giuseppe Bruno, Stefano Francesco Cappa et al. · 2025 · Neurological Sciences
33. TCnet: A Novel Strategy to Predict Target Combination of Alzheimer’s Disease via Network-Based Methods
    Chengyuan Yue, Baiyu Chen, Fei Pan, Ze Wang, Hongbo Yu, Guixia Liu, Weihua Li, Rui Wang, Yun Tang · 2025 · Journal of Chemical Information and Modeling
34. Comparing and combining TSPO-PET tracers in tauopathies
    Harry Crook, Nicolai Franzmeier, Nesrine Rahmouni, Johannes S. Gnörich, Tim D. Fryer, Young T. Hong, Sebastian Niclas Roemer, Carla Palleis, Alexandra Strauss, Peter Simon Jones et al. · 2025 · European Journal of Nuclear Medicine and Molecular Imaging
35. Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations
    So Yeon Jeon, Min Soo Byun, Hye Ji Choi, Yoon Hee Kim, Chung Hee Gwag, Yoonseok Oh, Jee Eun Park, Dahyun Yi, Gijung Jung, Hyejin Ahn et al. · 2025 · Alzheimer s & Dementia
36. Papaverine-Derived Dual-Active Modulator Ameliorates Alzheimer’s Disease Pathology in Aged APP/PSEN1 Transgenic Mice
    Ashish Kumar, Madhu Ramesh, Jikesh Bhoi, Thimmaiah Govindaraju · 2025 · Journal of Medicinal Chemistry
37. Development and Fabrication of Mesoporous Silica Nanoparticle Loaded in Situ Nasal Gel of Scutellarin for Alzheimer’s Disease
    Someshwar Dattatraya Mankar, Prashika Shinde, Suhas Shivaji Siddheshwar · 2026 · BioNanoScience
38. Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease
    Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, Suzanne E. Schindler, Shorena Janelidze, Anna Orduña Dolado, Divya Bali, Richard J. Perrin, John C. Morris, Tammie L.S. Benzinger et al. · 2026 · JAMA Neurology
39. PLAN—Dementia literacy education and navigation for Korean elders with probable dementia and their caregivers: Rationale, methods, and design of a community-based, randomized, controlled, multi-site clinical trial
    Hae-Ra Han, Nancy Perrin, Simona C. Kwon, Jin Hui Joo, Ji-Young Yun, Deborah Min, Hochang Benjamin Lee · 2024 · Contemporary Clinical Trials
40. Factors associated with adherence to tablet‐based cognitive training: J‐MINT study
    Taiki Sugimoto, Kazuaki Uchida, Kenji Sato, Yoko Yokoyama, Ayaka Onoyama, Kosuke Fujita, Yujiro Kuroda, Satomu Wakayama, Hidenori Arai, Takashi Sakurai et al. · 2025 · Alzheimer s & Dementia Translational Research & Clinical Interventions
41. Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption
    Jonathan M. Schott, Charles R. Marshall · 2025 · Arquivos de Neuro-Psiquiatria
42. Alzheimer’s Dementia Targeting by Plant-Derived 2,6-Dimethoxybenzoic Acid: In vitro, DFT and Molecular Docking Study
    E. Eunice, Johanan Christian Prasana · 2025 · Asian Journal of Chemistry
43. Integrative snRNA‐seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease
    Martin C. Nwadiugwu, Md. Selim Reza, Boluwatife Afolabi, Demetrius M. Maraganore, Hui Shen, Hong‐Wen Deng · 2025 · Clinical and Translational Medicine
44. Significance of NMDA receptor-targeting compounds in neuropsychological disorders: An in-depth review
    Fatemeh Forouzanfar, Amir Mahmoud Ahmadzadeh, Ali Mohammad Pourbagher‐Shahri, Ali Gorji · 2025 · European Journal of Pharmacology
45. The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer’s Dementia: A Systematic Review
    Alyaa Mostafa, Stephanie Tiu, Farooq Ahmed Khan, Nusrath A Baig · 2025 · Annals of Indian Academy of Neurology
46. Alzheimer’s disease and the mathematical mind
    Travis Thompson, Bradley Z. Vigil, Robert S. K. Young · 2024 · Brain Multiphysics
47. An Overview of Glutaminyl Cyclase as a Promising Drug Target for Alzheimer’s Disease
    Rasajna Madhusudhana, Emily Boyle, Yana Cen · 2025 · Biomedicines
48. Synthetic control methods for n‐of‐1 and parallel‐group trials in Alzheimer's disease: A proof‐of‐concept study using the I‐CONECT
    Chao‐Yi Wu, Liu Chen, John R. Dickson, Bo Zhang, Steven Edward Arnold, Hiroko Hayama Dodge · 2025 · Alzheimer s & Dementia
49. Preclinical evidence and potential mechanisms of tanshinone ⅡA on cognitive function in animal models of Alzheimer’s disease: a systematic review and meta-analysis
    Yuanhang Rong, Qinqing Li, Yuzhong Du, Wenting Wang, Wenna Su, Junlong Zhang, Wenbin He · 2025 · Frontiers in Pharmacology
50. Rivastigmine Templates with Antioxidant Motifs—A Medicinal Chemist’s Toolbox Towards New Multipotent AD Drugs
    Inês Dias, Marlène Emmanuel, Paul Vogt, Catarina Guerreiro-Oliveira, Inês Melo-Marques, Sandra M. Cardoso, Rita Cardoso Guedes, Sı́lvia Chaves, Maria Amélia Santos · 2025 · Antioxidants
51. Design, Synthesis and Biological Evaluation of Chromeno[3,4- b ]xanthones as Multifunctional Agents for Alzheimer’s Disease
    Daniela Malafaia, Natércia F. Brás, Anna Sampietro, Inês Quintelas, Pedro Ferreira, Lúcia Melo, Joana Saavedra, Loreto Martínez‐González, Marisa Pereira, Jéssica Sarabando et al. · 2025 · ACS Chemical Neuroscience
52. Delivery of monoclonal antibodies to the brain: the impact of nanocarrier structure
    Laura Pineiro‐Alonso, Inés Rubio-Prego, Ana M. López-Estévez, Pablo Garrido‐Gil, Rita Valenzuela, José Luis Labandeira-García, Pablo Aguiar, Ana Isabel Rodriguez-Perez, Marı́a José Alonso · 2025 · Drug Delivery and Translational Research
53. The involvement of HIF-1α–dependent paracrine factors in Alzheimer’s disease
    Victoria I. Zhdankina, Elizaveta S Perepelitsa, Anna V. Blagova, Yulia K. Komleva, Tatiana I. Baranich, Alla B. Salmina · 2025 · Reviews in the Neurosciences
54. Targeting Oligodendrocyte Dysfunction in Alzheimer’s Disease: a New Frontier for Drug Repurposing with Antihistamines and Serotonin Receptor Agonists
    Sharanappa Gurikar, Syed Sagheer Ahmed, Bharathi Doddlu Raghunatahanaidu · 2025 · Journal of Molecular Neuroscience
55. Interplay between CD33 and TREM2 in Alzheimer’s Disease: Potential Mechanistic Insights into Microglial Function in Amyloid Pathology
    Elizabeth Toyin Akinluyi, Kei Takahashi, Meghan G. Connolly, Wayne W. Poon, Matthew Scott Macauley · 2025 · ACS Chemical Neuroscience
56. Consideration of sex as a biological variable over the history of the 5xFAD Alzheimer’s Disease mouse model
    Julia Neuharth, K. Hernandez, J. Bernholtz, Hadley Edwards, Adele Stewart · 2025 · Biology of Sex Differences
57. Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-β pathology
    Przemysław Radosław Kac, Armand González‐Escalante, Marta Milà‐Alomà, Nicholas James Ashton, Mahnaz Shekari, Paula Ortiz‐Romero, Michael Turton, Peter Harrison, Henrik Zetterberg, Juan Domingo Gispert et al. · 2025 · Journal of Neurology
58. Advances in the drug treatment of Alzheimer’s disease: pathophysiology and mechanisms of action
    Joseph Nowell, Harry Crook, Mony J. de Leon, Paul Edison · 2026 · BMJ
59. A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease
    Mohamed Mahmoud Hafez, Haidy A. Abbas, Nabil A. Shoman, Ayman A. Soubh, Omnia Aly, Mohamed F. Sallam, Mahmoud A. Seliem, Fady A. Malaak · 2026 · Journal of Neurology
60. Porcine plasma-derived extracellular vesicles orchestrate multi-target neuroimmune reconfiguration to alleviate Alzheimer’s disease pathology in a 5×FAD mouse model
    Xiaoyang Lu, Yiling Jiang, Xiuqing Lin, Y X Zhang, Q Liu, Shouwen Chen · 2026 · Journal of Neuroinflammation
61. Hierarchical-circular model of biological memory: a multilevel hypothesis for pathogenesis and allostatic integrity in Alzheimer’s disease and related dementias
    Samuel Ruesga Mundo · 2026 · Frontiers in Dementia
62. Design, synthesis and biological evaluation of novel pyrazolinone derivatives as multifunctional ligands for the treatment of Alzheimer’s disease
    Huabo Wang, Yulu Wu, Anran Liu, Siyi Li, Peng Zhu, Jianguo Zuo, Ying Kuang, Jiaming Li, Xueyang Jiang · 2024 · Bioorganic Chemistry
63. Fluorescence imaging of homocysteine dynamics: Complementary diagnostic applications in Alzheimer's disease
    Guoxing Yin, Yitong Sun, Yajing Luo · 2025 · Analytica Chimica Acta
64. Broad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design
    Michael K. Leuchter, Hanadi Ajam Oughli, Kelly A. Durbin, NICHOLAS J. JACKSON, David A. Elashoff, Timothy S. Chang, Juliana Corlier, Doan Ngo, Cole Matthews, Darice Y. Wong et al. · 2025 · Alzheimer s & Dementia Translational Research & Clinical Interventions
65. Past, present, and future of serotonin-targeting therapeutics for Alzheimer’s disease: Perspectives from DNA methylation
    Yanzhi Liu, Luca Aquili, Kah-Hui Wong, Zhi-Liang Lu, Lee Wei Lim · 2025 · Ageing Research Reviews
66. A meta‐analysis and systematic review of interventions to prevent or treat cognitive decline related to Alzheimer's disease in adults with Down syndrome
    Emily E. Munn, Anna Montelongo, Viraj K. Patel, Jill C. Fodstad, Mary R. Ciccarelli, Lauren T. Ptomey, Melissa M. Pangelinan · 2025 · Alzheimer s & Dementia
67. Detection of extracellular amyloid beta aggregates by an Aducanumab-based synNotch receptor: an in vitro proof-of-concept study
    Nicholas J. Bergo, Suckwon Lee, Cynthia J. Siebrand, Zachary Mayeri, Julie Kay Andersen, Chaska C. Walton · 2025 · Journal of Translational Medicine
68. Central role of brain regulatory T cells in the inflammatory cascade in Alzheimer’s disease
    Germán Plascencia‐Villa, Rudolph J. Castellani, George L. Perry · 2024 · Proceedings of the National Academy of Sciences
69. Proteomic analysis and experimental validation reveal the blood–brain barrier protective of Huanshaodan in the treatment of SAMP8 mouse model of Alzheimer’s disease
    Yunfang Su, Ningning Liu, Pan Wang, Congcong Shang, Ruiqin Sun, Jinlian Ma, Zhonghua Li, Huifen Ma, Yiran Sun, Zijuan Zhang et al. · 2024 · Chinese Medicine
70. Psychoactive Plant Database: a phytochemical resource for neurological drug discovery
    Harjot Kaur, Monika Gupta, Zabeer Ahmed, Amit Nargotra · 2025 · Frontiers in Pharmacology
71. Single-cell digital twins identify drug targets and repurposable medicine in Alzheimer’s disease
    Yunxiao Ren, Ming Hu, Yang Eric Li · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
72. Portulaca oleracea L. Methanolic Extract Protects the Brain of Male Rats Against Alzheimer’s Disease
    Haddad A. El Rabey, Samar M. Rezk, Seham A. Mahmoud, Zienab Abdallah, Mennatallah Loutfy, Adel I. Alalawy, Yasmene F. Alanazi, Heba Sheta, Nadia Bakry · 2025 · Scientifica
73. Management of Patients With Mild Cognitive Impairment in the Era of Anti-Amyloid Therapy
    Graham A. McLeod, Aaron R. Switzer, Luca Bartolini, Alonso Gonzalo Zea Vera, Eric Edward Smith, Aravind Ganesh · 2025 · Neurology Clinical Practice
74. Is screening for Alzheimer’s disease ready for prime time? Ask Wilson and Jungner
    Miyo K. Chatanaka, Michael Loren, Eleftherios P. Diamandis · 2025 · Critical Reviews in Clinical Laboratory Sciences
75. Combinations of multimodal neuroimaging biomarkers and cognitive test scores to identify patients with cognitive impairment
    Yuriko Nakaoku, Soshiro Ogata, Kiyotaka Nemoto, Chikage Kakuta, Eri Kiyoshige, KANAKO TERAMOTO, Kiyomasa Nakatsuka, Gantsetseg Ganbaatar, Masafumi Ihara, Kunihiro Nishimura · 2025 · Frontiers in Aging Neuroscience
76. A Systematic Review of Neuroprotective Effects of Mangosteen and its Xanthones Against Oxidative Stress and Inflammation
    Hin Yee Thew, Yong Chiang Tan, Yong Sze Ong, Bey Hing Goh, Kooi Yeong Khaw · 2025 · Planta Medica
77. Advancing histone deacetylase 6 (HDAC6) as a promising therapeutic target for Alzheimer’s disease: from molecular insights to clinical prospects
    Wei Zhang, Yueyang Zhang, Yongle Wang, Changning Wang, Can Martin Zhang · 2025 · Frontiers in Drug Discovery
78. Kinetic Model with Feedback Cycle for Age-Dependent Amyloid Beta Accumulation in Mice
    Vivian Tyng, Michael E. Kellman · 2025 · International Journal of Molecular Sciences
79. Investigating the ameliorative effect of Kalanchoe pinnata on neuroinflammation-associated Alzheimer’s disease using network pharmacology, molecular docking, and in vitro studies
    Pratima Khandayataray, Meesala Krishna Murthy · 2025 · Journal of Computer-Aided Molecular Design
80. Efficacy of a multidomain intervention in older adults with vascular risks: The Japan‐Multimodal Intervention Trial for the Prevention of Dementia (J‐MINT)
    Taiki Sugimoto, Kazuaki Uchida, Yoko Yokoyama, Ayaka Onoyama, Hisashi Noma, Hidenori Arai, Takashi Sakurai, J‐MINT study group · 2025 · Alzheimer s & Dementia
81. Neurophysiological biomarker extraction through decoupled attention mechanisms and EEG signal processing in Alzheimer’s disease and frontotemporal dementia
    Alaa Hussein Abdulaal, Morteza Valizadeh, Mehdi Chehel Amirani · 2026 · Biomedical Signal Processing and Control
82. Artificial Intelligence to Guide Repurposing of Drugs
    Zhimin Fu, Yuxin Yang, Mina K. Chung, Feixiong Cheng · 2026 · Annual Review of Medicine
83. Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies
    Ankita Kumari, Xin-An Zeng · 2026 · Nutrients
84. Distinct and Overlapping Neuroprotective Efficacy of Silk Lutein and Sericin-Derived Oligopeptides from Yellow Silk Cocoons in Rodent Models of Aβ-Induced and Age-Related Cognitive Decline
    Pornnarin Taepavarapruk, Virakboth Prum, Manote Sutheerawattananonda · 2026 · International Journal of Molecular Sciences
85. Peptide-Based Therapeutics for Alzheimer’s Disease: Medicinal Chemistry, AI-Guided Computational Design, and Blood–Brain Barrier Delivery
    Abdulaziz Hassan Al Khzem, Mohamed Sayed Gomaa · 2026 · Drug Design Development and Therapy
86. A Polypharmacology-Driven Approach to Alzheimer’s Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) Inhibitors
    Stefania Demuro, Debora Russo, Ilaria Penna, Siranuysh Grabska, Hovakim Grabski, Andrea Dalle Vedove, Aurora Valeri, Conall Sauvey, Giuliana Ottonello, Maria Summa et al. · 2026 · Journal of Medicinal Chemistry
87. Anti-amyloid immunotherapy in Alzheimer’s disease: The new dawn emerging from 179 clinical trials
    Longmin Fan, Haitao Jiang, Zheyu Zhang · 2024 · Pharmacological Research
88. A Combined Computational and Experimental Approach to Studying Tropomyosin Kinase Receptor B Binders for Potential Treatment of Neurodegenerative Diseases
    Duc Duy Nguyen, Sally Mansur, Lukasz M. Ciesla, Nora E. Gray, Shan Zhao, Yuping Bao · 2024 · Molecules
89. Alzheimer's disease: part 2 – the present
    Ricardo Nitríni · 2024 · Arquivos de Neuro-Psiquiatria
90. Gut-Brain Axis and a Systematic Approach to Alzheimer’s Disease Therapies
    Jinhe Li, Huilin Mou, Ranran Yao · 2025 · Brain Science Advances
91. Clinicopathological Correlations of Neurodegenerative Diseases in the National Brain Biobank of Korea
    Young Hee Jung, Jun Pyo Kim, Hee Jin Kim, Hyemin Jang, Hyun Jeong Han, Young Ho Koh, Duk Lyul Na, Yeon‐Lim Suh, Gi Yeong Huh, Jae‐Kyung Won et al. · 2025 · Journal of Clinical Neurology
92. Simulation and one-ring prototyping of 1 mm-rod-resolution hemispherical brain PET with TOF-DOI detectors
    K Narita, Go Akamatsu, Eiji Yoshida · 2025 · Physics in Medicine and Biology
93. Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease
    Chong-Lei Fu, Xuehui Li, Xiaoxing Liu, Yongbo Zheng, Xiangxian Ma, Bo Zhang, Si Xuan Chen, Lingming Hu, Sizhen Su, Xiaokun Wang et al. · 2025 · Translational Neurodegeneration
94. The Missing Link in Antiamyloid Therapy
    Pravat Kumar Mandal, Joseph C. Maroon, Rimil Guha Roy · 2025 · ACS Chemical Neuroscience
95. Longitudinal Analysis of Electronic Health Records Reveals Medical Conditions Associated with Subsequent Alzheimer’s Disease Development
    Xue Yun Zhong, Gengjie Jia, Zhijun Yin, Kerou Cheng, Andrey Rzhetsky, Bingshan Li, Nancy Jean Cox · 2025 · medRxiv
96. Polygenic Hazard Score for Predicting Age-associated Risk of Alzheimer’s Disease in European Populations: Development and Validation
    Bayram Cevdet Akdeniz, Shahram Bahrami, Espen Hagen, Julian Fuhrer, Vera Fominykh, Alexey A. Shadrin, Tahir Tekin Filiz, Lavinia Athanasiu, Benjamin Grenier‐Boley, Céline Bellenguez et al. · 2025 · medRxiv
97. Advancements in Alzheimer’s Disease Biomarkers: Emerging Protein Targets for Early Diagnosis and Therapeutic Intervention
    Mst Muslima Khatun, MO Oni, Md. Shadin, B S M Bodiuzzaman · 2025 · Journal of Medicinal Chemistry and Therapeutics
98. Evaluating the Accuracy of Web-Based and In-Clinic Subjective Cognitive Decline Assessments in Detecting Cognitive Impairment: Multicohort Study
    Jae Myeong Kang, Manchumad Manjavong, Adam Diaz, Miriam Thiel Ashford, Anna Aaronson, Joseph Eichenbaum, R. Scott Mackin, Rachana Tank, Melanie Jayne Miller, Bernard Landavazo et al. · 2025 · Journal of Medical Internet Research
99. The efficacy and pharmacological mechanism of Guilingji to prevent Alzheimer’s disease
    Fengrui Hu, Yaling Lei, Rui Han, Bo Yang, Yanlin Liang, Jing Luan, Bei Zhang, Shan Wang, Xingchun Gou · 2025 · Alzheimer s Research & Therapy
100. Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab
     Emma H. Doud, Kasi Hansen, Kathryn A. Haynes, Kierra Eldridge, Jaison Arrivalagan, Nitin B. Charbe, Lais Da Silva, Sara K. Quinney, Amber L. Mosley, Stacey J. Sukoff Rizzo et al. · 2025 · mAbs